Info zur Galavit-Produktion
Indian Business Review vom 15 July 2000, Vol. III No. 7
KEE PHARMA TO LAUNCH 12 BIO-TECH PRODUCTS
The Delhi-based Kee Pharmaceuticals Ltd (KPL) is planning to launch at
least 12 new products in the biotechnology segment in the next three years.
These include Recombinant Streptokinase (which dissolves intra-coronary clots
to prevent fatal heart attacks), Epidermal Growth Factor (a healing and
antiseptic agent for treatment of burns) and Gamma Interferon (for
auto-immune diseases such as rheumatoid Arthritis and sclerosis).
Other new products planned are Interferon natural and interferon alpha 2b,
Recombinant Interleukin IB, Recombinant Erythropoietin, GALAVIT and
Rabies vaccine. "Some of these products will be launched by the company for the
first time in India. With the launch of these products, the company will
mark its presence in various therapeutic segments, especially in the
field of oncology and cardiology and immunology,'' Mr. Anil Motihar, Managing
Director, KPL said.
"The company has already applied for the trademark registration for six
new products. The first product -- Streptokinase (brand name - Cardiostrep)
will be launched in September this year,'' Mr. Motihar said. It has launched a
new division 'Kee Biogenetics' for its biotechnology products. It has tied
up with Heber Biotec, S.A. of Cuba, which is currently working on some
advanced biotechnology products.
KPL has also tied up with the State Scientific Centre Research Institute,
Institute of Polio Myelitis and the centre of modern medicine `Medicor'.
All these institutes are acclaimed in the field of biotechnology products
and vaccines in Russia. The company is also in talks with the Bangalore-based
Biotech Company -- Biocon -- for a synergistic arrangement to manufacture
Hepatitis B and cancer drugs in India.
Letzte Bearbeitung dieser Seite am: 27.11.2000